Jenburkt Pharmaceuticals Ltd (JENBURPH) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Jenburkt Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Counter Cyclical Investment Pvt Ltd
Acquisition/ Disposal of Shares · 04 Nov 2026, 9:20 pm
Counter Cyclical Investments Increases Stake in Jenburkt Pharmaceuticals to 5.11% Counter Cyclical Investments Private Limited (PMS), along with its clients (PAC), acquired 4,608 equity shares (0.10% stake) of Jenburkt Pharmaceuticals Ltd via open market purchases on 3rd Nov'26. Following the transaction, the non-promoter entity's total holding in the target company increased from 220,931 shares (5.01%) to 225,539 shares, representing 5.11% of the total voting and diluted share capital comprising 4,413,300 equity shares.
Outcome of the Board Meeting held today on 03rd November, 2026.
Outcome · 03 Nov 2026, 11:30 pm
Standalone Unaudited Financial Results for the quarter and half year ended on 30th September, 2026.
Financial Result · 03 Nov 2026, 11:26 pm
Jenburkt Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lacs) ■ Revenue: 4,832 (+6.1% YoY | +36.1% QoQ) ■ EBITDA: 1,302 (-0.7% YoY | +116.0% QoQ) ■ EBITDA Margin (%): 26.9 (-183 bps YoY | +997 bps QoQ) ■ PAT: 1,021 (+0.5% YoY | +73.5% QoQ) ■ EPS (INR): 23.1 (+0.4% YoY | +73.4% QoQ)
Jenburkt Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Standalone Unaudited ....
Intimation · 03 Nov 2026, 5:30 am
Jenburkt Pharmaceuticals Schedules Board Meeting to Consider Q2 FY27 Results Jenburkt Pharmaceuticals Limited has scheduled a meeting of its Board of Directors on 3rd Nov'26 to consider and approve the standalone unaudited financial results for the quarter and half year ended 30th Sep'26.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Counter Cyclical Investment Pvt Ltd
Acquisition/ Disposal of Shares · 12 Oct 2026, 11:11 pm
Counter Cyclical Investments Crosses 5% Stake in Jenburkt Pharmaceuticals Counter Cyclical Investments Private Limited acquired 326 equity shares (0.01% stake) in Jenburkt Pharmaceuticals Ltd via an open-market transaction on 9th Oct'26. Following this acquisition on behalf of its PMS clients, the acquirer's aggregate holding increased from 2,20,605 shares (4.99%) to 2,20,931 shares, crossing the statutory 5% threshold to reach 5.01% of the company's total paid-up equity share capital of 44,13,300 shares. Consequently, disclosures were submitted under Regulation 29(1) of SEBI SAST Regulations, 2011.
Intimation regarding admission of Equity shares of the Company under " Permitted to trade" category on National Stock Exchange of India Limited.
Others (Uncategorized) · 22 Sept 2026, 6:50 pm
Jenburkt Pharmaceuticals Equity Shares Admitted Under NSE Permitted to Trade Category Jenburkt Pharmaceuticals informed BSE that its equity shares were admitted to dealings on NSE's Capital Market Segment under the "Permitted to Trade" category effective 17th Aug'26, pursuant to NSE Circular dated 14th Aug'26. The company clarified that it has not applied for an NSE listing; its shares remain listed exclusively on BSE. The trading facility on NSE operates strictly under the exchange's permitted category without separate direct communication or application from the company.
Intimation about Resignation of a Senior Management Personnel of the Company.
Change in Management · 18 Sept 2026, 9:53 pm
Jenburkt Pharmaceuticals Senior VP Vinay Bhatt Resigns Jenburkt Pharmaceuticals announced the resignation of Vinay Bhatt, Senior Vice President – International Business and Senior Management Personnel, effective 18th Sep'26 due to personal reasons. Bhatt is stepping down after a 21-year tenure following operational and strategic discussions with management. A handover process will be coordinated to ensure international business continuity.
Re-Appointment of Shri. Dilip H. Bhuta (DIN 01357252) as Whole Time Director and CFO of the Company for the Period of 05 years from 01st April, 2027 to 31st March, 2032, Approved with requisite ....
Change in Management · 05 Sept 2026, 3:04 am
Submission of consolidated Voting Results and Scrutinizer''s Report on all the Resolutions as set out in the Notice Convening the 41st AGM of the Company held on 04th September, 2026.
Annual General Meeting · 05 Sept 2026, 2:53 am
Proceedings of the 41st Annual General Meeting of the Company held on Friday, 04th September, 2026.
Annual General Meeting · 05 Sept 2026, 2:10 am
Summary of the proceedings of the 41st Annual General Meeting of the Company held on Friday, 04th September, 2026.
Annual General Meeting · 05 Sept 2026, 2:05 am
Pursuant to Regulation 30 Read with Schedule III of the SEBI(Listing Obligations and Disclosure Requirnments ) Regulations 2015, we hereby inform you about the change in Senior Manaaement ....
Change in Management · 04 Sept 2026, 6:10 pm
Jenburkt Pharmaceuticals Elevates Prem Bhuta to AVP Strategic Initiatives Jenburkt Pharmaceuticals has elevated Prem Ashish Bhuta to Associate Vice President of Strategic Initiatives, effective 4th Sep'26. As a newly designated Senior Management Personnel related to the Promoter and CMD, Bhuta will drive cross-functional business transformation. Since joining in Jul'21, he has demonstrated strong operational capability by building the ZIXA Strong OTC brand and executing critical technology modernizations, including deploying a real-time sales tracking system for a 700-member field force. His advancement signals leadership continuity and a strategic focus on digital integration within Jenburkt's operations.
Standalone Unaudited Financial Results for the quarter ended on 30th June, 2026.
Financial Result · 07 Aug 2026, 1:35 am
Jenburkt Pharma Q1FY27 PAT Falls 24.5% YoY Amid Higher Expenses Jenburkt Pharmaceuticals reported a 24.5% YoY decline in Profit After Tax to ₹588.56 Lacs for Q1FY27, down from ₹779.18 Lacs. Revenue from operations remained flat at ₹3,551.20 Lacs. The profit decline was driven by a 10.4% YoY increase in total expenses to ₹3,025.61 Lacs, led by higher employee benefit and other expenses. Consequently, Profit Before Tax fell 33.5% YoY to ₹676.91 Lacs. Basic and diluted EPS for the quarter stood at ₹13.34, a significant drop from ₹17.66 in Q1FY26.
Outcome of the Board Meeting held today on 06th August, 2026.
Outcome · 07 Aug 2026, 1:29 am
Jenburkt Pharma Q1FY27 Net Profit Declines 24.5% YoY Jenburkt Pharmaceuticals reported a Profit After Tax of ₹588.56 Lacs for Q1FY27 ending 30th Jun'26, a 24.5% YoY decline and a 45.8% QoQ drop. Revenue from Operations remained flat YoY at ₹3551.20 Lacs. The significant profit reduction was driven by a 10.5% YoY increase in total expenses to ₹3025.61 Lacs, primarily due to higher employee benefit costs. Consequently, Profit Before Tax fell 33.5% YoY to ₹676.91 Lacs. Basic and Diluted EPS for the quarter stood at ₹13.34, down from ₹17.66 YoY.
Notice of the 41st Annual General Meeting of the Company Schedule to be held on Friday, 04th September, 2026, through VC/OAVM.
Annual General Meeting · 03 Aug 2026, 9:25 pm
Submission of the Annual Report for the FY 2025-26, containing Audited Standalone Financial Statements, Auditors Report and Directors Report and the Notice convening 41st Annual General ....
Others (Uncategorized) · 03 Aug 2026, 8:42 pm
Jenburkt Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve standalone unaudited ....
Intimation · 06 Aug 2026, 5:30 am
Jenburkt Pharma Board Meeting on 06 Aug'26 to Approve Q1 Results Jenburkt Pharmaceuticals has scheduled a Board of Directors meeting for 06 Aug'26. The agenda includes the consideration and approval of the company's standalone unaudited financial results for the quarter ended 30 Jun'26. This announcement is made in compliance with SEBI's Listing Obligations and Disclosure Requirement Regulations, 2015.
Intimation of shifting of Registered Office of the Company within the local limits of city of Mumbai.
Others (Uncategorized) · 14 Jul 2026, 12:13 am
Jenburkt Pharma Shifts Registered Office Within Mumbai Effective 21st Jul'26 Jenburkt Pharmaceuticals announced its Board approved shifting the company's registered office within Mumbai, effective 21st Jul'26. The office will move from Nirmala Apartments, Jay Prakash Road, Andheri West, to the 14th floor, Unicorn, Dattaji Salvi Marg, Andheri West. Other details, including telephone number, email, website, and Registrar of Companies jurisdiction, remain unchanged. This administrative update is not expected to have a material financial impact on the company's operations.
The Company has fixed Friday, 28th August, 2026, as the Record date for the Payment of Dividend for the Financial Year 2025-26 as well as cut-off date for Remote e-voting and e-voting during ....
Dividend · 06 May 2026, 8:29 pm
Jenburkt Pharma Sets Record Date for FY26 Dividend Jenburkt Pharmaceuticals has set Fri, 28th Aug'26 as the record date for determining shareholder eligibility for the dividend for the financial year ending 31st Mar'26. The dividend, if approved at the 41st Annual General Meeting (AGM) scheduled for 4th Sep'26, will be paid within 30 days of the AGM. The 28th Aug'26 date also serves as the cut-off for e-voting eligibility for the meeting.
The Board of Director of the Company recommeded a dividend of Rs.20.70 (207%) per equity share of Rs.10/- each on 4413300 equity shares of the Company for the financial year 2025-26, Subject ....
Dividend · 06 May 2026, 1:22 am
Jenburkt Pharma Q4FY26 Results, FY26 Dividend, and Key Appointments Jenburkt Pharmaceuticals reported Q4FY26 PAT at ₹10.85 Cr, up 27.1% YoY, on revenue of ₹44.63 Cr, up 8.7% YoY. For FY26, PAT grew 8.3% YoY to ₹34.74 Cr, while revenue increased 11.2% YoY to ₹168.74 Cr. The Board recommended a dividend of ₹20.70 per share (207%) for FY26. Additionally, the Board approved the re-appointment of Shri Dilip H. Bhuta as Whole Time Director & CFO for five years from 01st Apr'27 to 31st Mar'32, subject to shareholder approval.
Re-appointment of Whole Time Director and CFO of the Company, subject to the approval of the members at the ensuing 41st Annual General meeting of the Company.
Change in Management · 06 May 2026, 1:16 am
Jenburkt Pharma Q4FY26 Results: Profit Up 27% YoY, Announces Dividend Jenburkt Pharmaceuticals reported a strong Q4FY26 with net profit rising 27.1% YoY to ₹108.5 Cr. Revenue from operations for the quarter grew 8.7% YoY to ₹446.2 Cr. For the full year FY26, net profit increased by 8.3% YoY to ₹347.4 Cr, while revenue was up 11.2% YoY at ₹1,687.4 Cr. The Board has recommended a dividend of ₹20.70 per share (207%) for FY26. Additionally, the Board approved the re-appointment of Shri Dilip H. Bhuta as Whole Time Director & CFO.
Standalone audited financial reults of the Company for the quarter and financial year ended on 31st March, 2026.
Financial Result · 06 May 2026, 1:05 am
Jenburkt Pharmaceuticals Limited - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lacs) ■ Revenue: 4463 (+8.7% YoY | +8.7% QoQ) ■ EBITDA: 1425 (+31.2% YoY | +31.2% QoQ) ■ EBITDA Margin (%): 31.9 (+547 bps YoY | +547 bps QoQ) ■ PAT: 1085 (+27.1% YoY | +27.1% QoQ) ■ EPS (INR): 24.6 (+27.1% YoY | +27.1% QoQ)
Outcome of Board Meeting Held on 05th May, 2026.
Outcome · 06 May 2026, 12:45 am
Jenburkt Pharmaceuticals Limited - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lacs) ■ Revenue: 4463 (+8.7% YoY | +8.7% QoQ) ■ EBITDA: 1425 (+31.2% YoY | +31.2% QoQ) ■ EBITDA Margin (%): 31.9 (+547 bps YoY | +547 bps QoQ) ■ PAT: 1085 (+27.1% YoY | +27.1% QoQ) ■ EPS (INR): 24.6 (+27.1% YoY | +27.1% QoQ)
Jenburkt Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2026 ,inter alia, to consider and approve the audited results ....
Intimation · 05 May 2026, 5:30 am
Jenburkt Pharma Board Meeting on 05 May'26 for Q4 Results and Dividend Jenburkt Pharmaceuticals has scheduled a Board of Directors meeting on 05 May'26. The primary agenda includes the approval of audited financial results for the quarter and financial year ended 31 Mar'26. The board will also consider the recommendation of a dividend for the financial year. This announcement is a key upcoming catalyst for the stock, pending the release of financial performance figures and potential shareholder payouts.
Pursuant to SEBI Circular dated 10th August, 2021, we hereby confirm that, for the financial year ended 31st March, 2026, Jenburkt pharmaceuticals Limited is "not a large corporate" as ....
Others (Uncategorized) · 14 Apr 2026, 6:48 pm
Jenburkt Pharma Confirms It Is Not a 'Large Corporate' Jenburkt Pharmaceuticals Limited (BSE: 524731) filed a disclosure on 14th Apr'26 confirming it is not classified as a 'large corporate'. This status applies for the financial year ended 31st Mar'26, as per the criteria outlined in SEBI Circular SEBI/HO/DDHS/CIR/2021/613. The classification exempts the company from certain regulatory requirements applicable to larger entities.